REAL AD-team at AD/PD 2026
March 21, 2026
AD/PD 2026 took place in Copenhagen, a meeting place for researchers, drug developers, and clinical experts in Alzheimer’s and Parkinson’s research. The REAL AD team participated with several presentations and posters during the conference.
Prof. Michael Schöll presented REAL AD results in the presentation “Associations Between Digital Cognition and Plasma Biomarkers for Preclinical Alzheimer’s Disease in the Population-based REAL AD Study”. He also participated as an invited speaker in the forum “Beyond One Size Fits All: Precision Drug Development, AI Methods, and Trial Design in AD/PD”.
Dr. Laura Stankeviciute presented results from the REAL AD study on modifiable lifestyle risk factors in the presentation “Modifiable Risk Factors are Associated with Plasma Biomarkers and Digital Cognition in the Population-based REAL AD Study”. Dr. Laura Stankeviciute also received the prestigious Junior Faculty Award from the AD/PD conference, an award given to promising early-career researchers.
Iris Bosch, project leader for REAL AD, presented a poster titled “Behind the Screens: Evaluating Collaborations and Partner Experiences in a Remote Preclinical Alzheimer’s Screening Study - Insights from REAL AD”, highlighting collaborations and partner experiences in the study.
We look forward to sharing more detailed updates on these study results in targeted posts in the near future.
We also had another lab member presenting her Alzheimer’s research during the conference, highlighting the breadth of ongoing projects within the REAL AD team. PhD student Stamatia Karagianni presented “Progression rates to Tau-PET positivity and cognitive impairment risk in preclinical Alzheimer's disease”, focusing on the risk of cognitive decline and the progression to Tau-PET positivity in preclinical Alzheimer’s disease.
